Patent · US Active

Humanized affinity matured anti-FcRn antibodies

US10822417B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignee

Syntimmune, Inc. · US

Inventors

Laurence J. Blumberg · New York, US
Richard S. Blumberg · Sharon, US
Susan Dana Jones · Boston, US
Derry Roopenian · Salsbury Cove, US
Robert George Edward Holgate · Royston, GB
Timothy David Jones · Babraham, GB
Arron Hearn · Ely, GB

Key dates

Filing date	Apr 25, 2017
Grant date	Nov 3, 2020
Priority date	—
Expiry date	Sep 3, 2037

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/765
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.